Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Otezla Is Amgen’s Main Growth Driver As Net Drug Pricing Declines

Without the newly purchased drug, Amgen’s 2020 sales would be flat, but the company hopes to enhance its psoriasis market push with its combined offering of Otezla, Enbrel and biosimilars.

Sales & Earnings Business Strategies Dermatology

Latest From Pricing Debate

Rx List Price Inflation Penalty Endorsed By US HHS Secretary

Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.

Legislation Medicare

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Health Technology Assessment Comparative Effectiveness

Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity

Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.

Medicare Pricing Debate

FDA Broke Catalyst's Orphan Exclusivity Due To Pricing, Not Clinical, Concerns, Firm Claims

Suit against agency reveals internal discussions to approve Jacobus' Ruzurgi despite Catalyst's orphan exclusivity for the same drug; Sen. Bernie Sanders urged FDA to address price of Catalyst's Firdapse (amifampridine).

FDA Legal Issues

Biopharma Needs A Deal On Drug Pricing As Shield Against Possible Democrat Wins – BIO’s Greenwood

Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.

Pricing Debate Elections

Trump Administration Signals Deference To Congress On Drug Pricing Policy

In a marked departure from previous years, budget proposal offers few specifics on cost reductions, but the $135bn savings estimate is a tacit endorsement of the Grassley-Wyden bill in the Senate.

Pricing Debate Legislation

UK To Cut Company Payments Under Statutory Pricing Scheme

Companies that are part of the statutory pricing scheme could pay up to £6m less in 2020 under government proposals to cut percentage payments on their sales to the National Health Service. 

United Kingdom Pricing Debate

UK Urged To Fund Rare Disease Treatments Immediately

Genetic Alliance UK says companies should be clear about how they price rare disease treatments and that the government should explain how it assesses affordability.

Europe United Kingdom

Drug Pricing Avoids The Limelight During State Of The Union Address

President Trump did not offer any new proposals on drug pricing during an evening featuring campaign theatrics on both sides. 

Pricing Debate Politics
See All
UsernamePublicRestriction

Register